As a first target indication, we focus on reconstructing the artery for patients suffering from below-the-knee chronic limb-threatening ischemia (CLTI), a pressing issue affecting over 3.5 million patients across the EU and the US.

CLTI causes severe blood flow restriction to the foot, which can lead to amputation. The current standard of card, plain old balloon angioplasty (POBA), is highly ineffective, with re-occlusions occurring within 3 to 6 months.

Consequently, 250.000 amputations are still performed every year.